The GLP-1 Shortage Ends: A Battle of Price and Legal Loopholes

Three GLP-1 weight-loss drugs approved in the US soared in price due to shortages, leading telehealth startups to partner with compounding pharmacies to sell them cheaply. However, with the FDA declaring the shortage over, this is about to change. Pharmacies are attempting various legal strategies to continue sales, including modifying dosages or adding ingredients, but their success is questionable. Meanwhile, pharmaceutical companies are launching new direct-to-consumer models with prices between high and low, and are taking steps to prevent dosage arbitrage. The outcome will affect millions relying on these drugs, offering a new perspective on innovation in pharmaceutical business models.